Breaking News, Collaborations & Alliances

FORMA, BI in R&D Alliance

Will focus on developing novel cancer drugs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim and FORMA Therapeutics have entered into a R&D collaboration to discover and develop novel drug candidates for the treatment of cancer. The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions. FORMA will receive a total of $65 million in upfront payments and research funding to screen for and optimize compounds against multiple oncology targets during the next four years. FORMA is eligible to receive as much as...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters